Register to chat with like-minded investors on our interactive forums.
The current KKPCF market cap is 899.73M. The company's latest EPS is JPY 214.1807 and P/E is 0.11.
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 89.23B | 74.98B | 76.03B | 72.98B | 72.04B |
| Operating Income | 26.22B | 17.79B | 14.07B | 6.11B | 9.47B |
| Net Income | 19.37B | 13.41B | 9.55B | 5.44B | 8.03B |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 157.88B | 163.33B | 165.18B | 166.33B | 171.62B |
| Total Liabilities | 29.41B | 27.07B | 26.86B | 29.49B | 27.87B |
| Total Equity | 128.47B | 136.26B | 138.33B | 136.84B | 143.76B |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 27.47B | 14.38B | 13.34B | 9.25B | 2.58B |
| Investing | -2.53B | -1.65B | -7.89B | -2.63B | -5.85B |
| Financing | -10.17B | -8.75B | -8.13B | -6.99B | -5.66B |
| Market Cap | 899.73M |
| Price to Earnings Ratio | 0.11 |
| Price to Sales Ratio | 0.01 |
| Price to Cash Ratio | 0.02 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | 46,782.07% |
| Shares Outstanding | 37.47M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 200 |
| 52 Week Change | 0.67% |
| 52 Week High | 28.00 |
| 52 Week Low | 22.30 |
| Spread (Intraday) | 12 (37.5%) |
| Company Name | Kaken Pharmaceutical Company Ltd (PK) |
| Address |
2-28-8 honkomagome bunkyo, tokyo 113-8650 |
| Website | https://www.kaken.co.jp |
| Industry | drugs-health r&d/testing labs (H8) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
